Information Provided By:
Fly News Breaks for August 31, 2015
MDCO
Aug 31, 2015 | 07:38 EDT
RBC Capital raised its price target on The Medicines Co as the firm says that a Phase I trial of the company's ALN-PCSsc treatment yielded better than expected results. The drug lowered LDL-C 50% for up to 4+ months and has the potential to be dosed every 3-6 months,RBC stated. The current standard of care must be dosed every two to four weeks, according to the firm ,which raised its probability of success and peak penetration estimates for the drug. RBC keeps an Outperform rating on the shares.
News For MDCO From the Last 2 Days
There are no results for your query MDCO